Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Q1 FY2024 Earnings Presentation
29 slides from Mankind Pharma's earnings presentation, August 2023
Slide 1: Investor Presentation Q1FY24
Mankind|ll> INVESTOR PRESENTATION QIFY24
Slide 2: Safe Harbour Statement
Safe Harbour Statement The statements, are as on date and may contain forward-looking statements like the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions regarding the financial position, business strategy, plans, t
Slide 3: Index
Index 01 Corporate Framework 03 Business Updates • Mankind at a Glance • Domestic Business • Key Strengths • Consumer Healthcare Business • Strategy Going Ahead • Export Business 02 Financial Performance 04 Additional Information • Key Performance Indicators • Key Financial Snapshot – Q1FY24 • Envir
Slide 4: Corporate Framework
ng Mankindlil> Serving Life Corporate Framework
Slide 5: Mankind Pharma at a Glance
Mankind Pharma at a Glance #1 Youngest 4 Rank in #4 Consumer Healthcare Prescriptions over in Top 5 of the By value in the brands ranked #1 in Market the last five years* IPM* IPM* their categories* Leadership INR 8,749 Crore 97% 20 15,000+ Domestic revenue # of INR 100 Cr+ brand FY23 Revenue Field
Slide 6: Key Strengths
Key Strengths India revenues contribute 97% of revenues in FY23 Focus on Focus on 75% of manufacturing in-house; track record of domestic Strong In- domestic innovation with commercialization of business Volume- house business “Dydrogesterone” manufacturing growth driven Avg. Volume growth of 3X in
Slide 7: Strategy Going Ahead
Strategy Going Ahead Increase the value of prescriptions in existing markets of strength by expanding market coverage; CVM moved from 62% in FY21 to 68% in FY23* Increasing share of chronic segment by growing presence in existing therapies (Insulin Glargine) and expansion into new therapies (Respira
Slide 8: Financial Performance
Cig Mankindil> Serving Life Financial Performance
Slide 9: Key Financial Snapshot – Q1FY24
Key Financial Snapshot – Q1FY24 Mr. Rajeev Juneja Vice Chairman & Managing Director “We have started the year on a healthy note, with strong double digit Segmental Revenue Break - Up growth in sales and profitability. The Pharma segment outperformed the IPM by 1.5X led by volume growth and highest e
Slide 10: Quarterly P&L Highlights
Quarterly P&L Highlights INR Crore Q1FY24 Q1FY23 YoY Growth Q4FY23 QoQ Growth Revenue from Operations 2,579 2,180 18% 2,053 26% Domestic Business 2,419 2,129 14% 1,972 23% Consumer Healthcare 208 193 8% 152 37% Exports Business 160 51 214% 81 98% Gross Profit 1,759 1,425 23% 1,379 28% EBITDA 660 460
Slide 11: Key Financial Metrics
Key Financial Metrics ROE* ROCE* Net Cash* (INR crore) 34% Dip on account Dip on account of acquisition of acquisition 28% 25% 25% 22% 1,727 23% 31% 25% 1,366 412 105 FY22 FY23 Q1FY23 Q1FY24 FY22 FY23 Q1FY23 Q1FY24 FY22 FY23 Q1FY23 Q1FY24 Cash Flow from Operations (INR crore) Net Operating Working C
Slide 12: Business Updates
ye Mankindil> Serving Life Business Updates
Slide 13: Domestic Business - Continued Outperformance
Domestic Business - Continued Outperformance Strong Growth in Domestic Revenue* Volume Outperformance of 3.2X INR Crore 16.7 8,453 9.7 7,595 2.6 4.3 0.1 1.4 FY22 FY23 Q1FY23 Q1FY24 2,129 2,419 -9.6 -10.6 FY22 FY23 Q1FY23 Q1FY24 IPM Growth Rate % Mankind Growth Rate % • Domestic Business witnessed a
Slide 14: Increasing Share of Chronic Segment
Increasing Share of Chronic Segment Increasing share of chronic segment that has a higher price realisation and lifetime value Consistent focus to increase chronic contribution 1.7 X outperformance to IPM chronic in Q1FY24 and 1.3 X in FY23 36 19 34 34 17 14 13 11 10 32 5 4 FY22 FY23 Q1FY23 Q1FY24 F
Slide 15: Across a Fast Growing Diversified Portfolio
..Across a Fast Growing Diversified Portfolio Diversified Therapy Presence (Sales Mix – Q1FY24) High Ranks across Acute and Chronic Areas Rank in FY 20-23 CAGR Therapy Areas CVM (Q1FY24) Mankind IPM Neuro / CNS 3% Anti- Anti-Infectives 4 11% 8% Others Infectives 13% Cardiovascular 3 17% 11% 9% Respi
Slide 16: Building Fast Growing Consumer Healthcare Franchise
Building Fast Growing Consumer Healthcare Franchise… Consumer Healthcare Segment Revenue INR Crore 692 589 193 208 FY22 FY23 Q1FY23 Q1FY24 • Consumer Healthcare segment witnessed a growth of 8% YoY and 37% QoQ • Secondary sales in Prega News®,HealthOKTM , Manforce® condoms up by 30%* YoY, 23%* YoY,
Slide 17: with Market Leading Brands
…with Market Leading Brands Dominant Brands in Consumer Healthcare #1 #1 #2 Condom Brand Pregnancy Test Kit Brand Antacid Powder Brand Market Share – 30% Market Share – 85% Market Share – 8% #8 #1 #1 Emergency Contraceptive Vitamins, Minerals, Nutrients Medicated Anti-Acne Brand Brand Brand Market S
Slide 18: DMF Quality Products At Mankind Prices
DMF Quality Products At Mankind Prices Mankind Pharma Sets New Industry Standard with First Company in India to offer DMF Quality API Unprecedented Display on Burj Khalifa, Reinforcing products at affordable prices Commitment to Excellence 18
Slide 19: Strong Corporate Identity Complements Brand Recall
Strong Corporate Identity Complements Brand Recall… Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Consumer Healthcare Brand Ambassadors 19
Slide 20: With Targeted Marketing Initiatives
…With Targeted Marketing Initiatives Prega News – Means Good News India's No.1* brand for condoms – • Targeted 360 degree communication with video sequencing Ads; • The idea behind the campaign was to populate the idea of vast range Optimizing the complete marketing funnel from awareness- of flavors
Slide 21: With Targeted Marketing Initiatives
…With Targeted Marketing Initiatives HealthOK - To drive brand awareness & connect at regional level Gas-O-Fast - India Ki Acidity Ka Asli Indian Solution • Ads in newspaper in the market of U.P. • Launched a 360 degree campaign in TV, Print, Radio, Digital & • Participated in events like Kanpur Mar
Slide 22: Exports Business Update
Exports Business Update Revenue from Exports INR Crore 296 187 160 51 FY22 FY23 Q1FY23 Q1FY24 • Exports business witnessed a growth of 214% YoY in Q1FY24 aided by certain one-off opportunities in the US • Focus on differentiated filings, including in-licensing for key markets • New integrated API/fo
Slide 23: Additional Information
Cig Mankindll> Serving Life y/ 4 Additional Information
Slide 24: Key Performance Indicators (as per ICDR Requirement post IPO)
Key Performance Indicators (as per ICDR Requirement post IPO) FY22 FY23 Q1FY23 Q1 FY24 Revenue from Operations within India as a percentage of revenue from 97.60% 96.62% 97.66% 93.79% operations % EBITDA* (INR Million) 20,038.00 19,130.61 4,596.78 6,595.41 EBITDA Margin (%) 25.75% 21.86% 21.09% 25.5
Slide 25: ESG: Organization wide focus on sustainable growth
ESG : Organization wide focus on sustainable growth Key Key Key New Highlights Initiatives Priorities Technologies Silver Award to Unit- 3, Paonta Sahib from Kaizen Hansei under Environment & ESG assessment. • 17,468 KL treated waste • ESG assessment • ESG Training to • Sikkim- Paddle dryer for wate
Slide 26: Shareholding Pattern
Shareholding Pattern BSE Ticker 543904 Retail , 1.1% Others, 0.8% FPI & Bodies NSE Symbol MANKIND Corporate, 17.7% Market Cap. (INR Crore)* 70,952 Mutual Funds , 3.9% % Free Float 23.5 Free Float Market Cap. (INR Crore) 16,674 Promoters, 76.5% Shares Outstanding (crore) 40.06 Industry Pharmaceutical
Slide 27: Q1FY24 Earnings Call Details
Q1FY24 Earnings Call Details Date 3rd August, 2023 Time 12 Noon IST Dial – In Details Universal Access Numbers +91-22-62801214/ +91-22-71158115 https://services.choruscall.in/DiamondPassRegistration/register?confirm Diamond Pass ationNumber=9990656&linkSecurityString=35ca196800 27
Slide 28: Annexure – Formulae
Annexure – Formulae • ROE = (Profit for the year) / (average total equity less cash) o Profit excludes interest income and gain on current investments measured at FVTPL • Adjusted ROE = (Adjusted profit for the year) / (average adjusted total equity less cash) o Profit excludes any M&A related impac
Slide 29: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Investor Relations – 011 - 46846700 Investor.relations@mankindpharma.com